Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT06350123
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 324 participants
- Sponsor
- Registry
-
NCT06350123 -
2023-509709-63-00
-
- Other papers using this trial's data
- Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Brazil, Bulgaria, Canada, China, Italy, Japan, Malaysia, Poland, Spain, Taiwan, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT06350123. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-01 (actual); primary completion 2025-05-09 (actual). Results posted on 2026-06-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
- Acronym
- MIRO-CKD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug)
- Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug)
- Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06350123- Content hash
15174b5fd0ff776c6d10b76886432c48f81ee3b3776d5779c099a4edd0173aa3